

Samuel R Denmeade

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/211520/samuel-r-denmeade-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

77
papers

5,445
citations

31
h-index

73
g-index

87
ext. papers

6,675
ext. citations

6.1
avg, IF

5.42
L-index

#	Paper	IF	Citations
77	Clinical Efficacy of Bipolar Androgen Therapy in Men with Metastatic Castration-Resistant Prostate Cancer and Combined Tumor-Suppressor Loss. <i>European Urology Open Science</i> , 2022 , 41, 112-115	0.9	0
76	Supraphysiologic Testosterone Induces Ferroptosis and Activates Immune Pathways through Nucleophagy in Prostate Cancer. <i>Cancer Research</i> , 2021 , 81, 5948-5962	10.1	3
75	TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1371-1382	2.2	22
74	Reversing the effects of androgen-deprivation therapy in men with metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2021 , 128, 366-373	5.6	1
73	Fatty Acid Synthesis in Prostate Cancer: Vulnerability or Epiphenomenon?. <i>Cancer Research</i> , 2021 , 81, 4385-4393	10.1	8
72	Targeting the spectrum of immune checkpoints in prostate cancer. <i>Expert Review of Clinical Pharmacology</i> , 2021 , 14, 1253-1266	3.8	2
71	Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer. <i>European Urology Oncology</i> , 2021 , 4, 447-455	6.7	20
70	A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts. <i>European Urology</i> , 2021 , 79, 692-699	10.2	17
69	Overcoming stromal barriers to immuno-oncological responses via fibroblast activation protein-targeted therapy. <i>Immunotherapy</i> , 2021 , 13, 155-175	3.8	6
68	Patterns of Recurrence and Modes of Progression After Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 , 109, 387-395	4	11
67	From Plant to Patient: Thapsigargin, a Tool for Understanding Natural Product Chemistry, Total Syntheses, Biosynthesis, Taxonomy, ATPases, Cell Death, and Drug Development. <i>Progress in the Chemistry of Organic Natural Products</i> , 2021 , 115, 59-114	1.9	0
66	Detection of Early Progression with F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy. <i>Journal of Nuclear Medicine</i> , 2021 , 62, 1270-1273	8.9	1
65	Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy. <i>European Journal of Cancer</i> , 2021 , 144, 302-309	7.5	3
64	Molecular and Clinical Characterization of Patients With Metastatic Castration Resistant Prostate Cancer Achieving Deep Responses to Bipolar Androgen Therapy. <i>Clinical Genitourinary Cancer</i> , 2021 , ,	3.3	3
63	Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer. <i>Prostate</i> , 2020 , 80, 407-414	4.2	11
62	Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, 650-659	13.4	297
61	Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors. <i>Oncogene</i> , 2020 , 39, 6935-6949	9.2	19

60	Microparticle Encapsulation of a Prostate-targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-resistant Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 2353-2362	6.1	1
59	A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma. <i>Oncologist</i> , 2020 , 25, 121-e213	5.7	8
58	Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 105, 948-956	4	21
57	Albumin-linked prostate-specific antigen-activated thapsigargin- and niclosamide-based molecular grenades targeting the microenvironment in metastatic castration-resistant prostate cancer. <i>Asian Journal of Urology</i> , 2019 , 6, 99-108	2.7	10
56	Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted F-DCFPyL PET/CT. <i>Annals of Nuclear Medicine</i> , 2019 , 33, 617-623	2.5	15
55	Risk of development of visceral metastases subsequent to abiraterone vs placebo: An analysis of mode of radiographic progression in COU-AA-302. <i>Prostate</i> , 2019 , 79, 929-933	4.2	0
54	An IL-2 proaerolysin fusion toxin that selectively eliminates regulatory t cells to enhance antitumor immune response. <i>Prostate</i> , 2019 , 79, 1071-1078	4.2	3
53	Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6	15
52	In Reply. <i>Stem Cells Translational Medicine</i> , 2019 , 8, 739-740	6.9	1
51	A Phase I Study to Assess the Safety and Cancer-Homing Ability of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Men with Localized Prostate Cancer. <i>Stem Cells Translational Medicine</i> , 2019 , 8, 441-449	6.9	33
50	A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer. <i>Prostate</i> , 2019 , 79, 1597-1603	4.2	14
49	Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage. <i>Journal of Clinical Investigation</i> , 2019 , 129, 4245-4260	15.9	39
48	PSA-alpha-2-macroglobulin complex is enzymatically active in the serum of patients with advanced prostate cancer and can degrade circulating peptide hormones. <i>Prostate</i> , 2018 , 78, 819-829	4.2	7
47	Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise. <i>Stem Cells Translational Medicine</i> , 2018 , 7, 651-663	6.9	119
46	PSA-selective activation of cytotoxic human serine proteases within the tumor microenvironment as a therapeutic strategy to target prostate cancer. <i>Oncotarget</i> , 2018 , 9, 22436-22450	3.3	5
45	Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. <i>Lancet Oncology</i> , 2018 , 19, 76-86	21.7	100
44	Clinical Applications of Molecular Imaging in the Management of Prostate Cancer. <i>PET Clinics</i> , 2017 , 12, 185-192	2.2	9
43	Androgen Receptor Splice Variants Are Not Substrates of Nonsense-Mediated Decay. <i>Prostate</i> , 2017 , 77, 829-837	4.2	2

42	Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2149-2156	2.2	279
41	Anticancer activities of emetine prodrugs that are proteolytically activated by the prostate specific antigen (PSA) and evaluation of in vivo toxicity of emetine derivatives. <i>Bioorganic and Medicinal Chemistry</i> , 2017 , 25, 6707-6717	3.4	13
40	A phase II randomized trial of Observation versus stereotactic ablative Radiation for Oligometastatic prostate CancEr (ORIOLE). <i>BMC Cancer</i> , 2017 , 17, 453	4.8	60
39	Extreme Response to High-dose Testosterone in BRCA2- and ATM-mutated Prostate Cancer. <i>European Urology</i> , 2017 , 71, 499	10.2	19
38	Detection fidelity of AR mutations in plasma derived cell-free DNA. <i>Oncotarget</i> , 2017 , 8, 15651-15662	3.3	19
37	Mesenchymal stem cell infiltration during neoplastic transformation of the human prostate. <i>Oncotarget</i> , 2017 , 8, 46710-46727	3.3	20
36	A phase II randomized trial of observation versus stereotactic ablative radiation for oligometastatic prostate cancer (ORIOLE).. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS5094-TPS5094	2.2	
35	Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study. <i>Prostate</i> , 2016 , 76, 1218-26	4.2	45
34	Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategy. <i>Prostate</i> , 2016 , 76, 703-14	4.2	18
33	A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer. <i>Biomaterials</i> , 2016 , 91, 140-150	15.6	55
32	Patterns of metastatic disease progression after treatment with first-line enzalutamide or abiraterone in castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, e16539-e16539	3.2	139
31	Challenges of conducting clinical trials of natural products to combat cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2016 , 14, 447-55	0.6	18
30	Mutational Analysis of Prostate-Specific Antigen Defines the Intrinsic Proteolytic Activity of the proPSA Zymogen. <i>Prostate</i> , 2016 , 76, 1203-17	4.2	2
29	Design, synthesis and cytotoxicity studies of dithiocarbamate ester derivatives of emetine in prostate cancer cell lines. <i>Bioorganic and Medicinal Chemistry</i> , 2015 , 23, 5839-45	3.4	15
28	Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study. <i>Science Translational Medicine</i> , 2015 , 7, 269ra2	17.5	149
27	A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination. <i>Prostate</i> , 2015 , 75, 1518-25	4.2	70
26	Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2015 , 1, 582-91	13.4	441
25	Protease-activated pore-forming peptides for the treatment and imaging of prostate cancer. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 659-68	6.1	10

24	AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. <i>New England Journal of Medicine</i> , 2014 , 371, 1028-38	59.2	1753
23	Prospective, randomized, double-blind, vehicle controlled, multicenter phase IIb clinical trial of the pore forming protein PRX302 for targeted treatment of symptomatic benign prostatic hyperplasia. <i>Journal of Urology</i> , 2013 , 189, 1421-6	2.5	51
22	Structural optimization, biological evaluation, and application of peptidomimetic prostate specific antigen inhibitors. <i>Journal of Medicinal Chemistry</i> , 2013 , 56, 4224-35	8.3	16
21	Proteolysis of complement factors iC3b and C5 by the serine protease prostate-specific antigen in prostatic fluid and seminal plasma. <i>Journal of Immunology</i> , 2013 , 190, 2567-74	5.3	16
20	Trypsin-like proteolytic contamination of commercially available psa purified from human seminal fluid. <i>Prostate</i> , 2012 , 72, 1233-8	4.2	4
19	Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer. <i>Prostate</i> , 2012 , 72, 1491-505	4.2	69
18	Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy. <i>Science Translational Medicine</i> , 2012 , 4, 140ra86	17.5	159
17	Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. <i>European Urology</i> , 2011 , 59, 747-54	10.2	46
16	Enzymatically active prostate-specific antigen promotes growth of human prostate cancers. <i>Prostate</i> , 2011 , 71, 1595-607	4.2	35
15	Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer. <i>Prostate</i> , 2010 , 70, 1600-7	4.2	67
14	Prostate-specific antigen is a "chymotrypsin-like" serine protease with unique P1 substrate specificity. <i>Biochemistry</i> , 2009 , 48, 3490-6	3.2	39
13	Potent and selective peptidyl boronic acid inhibitors of the serine protease prostate-specific antigen. <i>Chemistry and Biology</i> , 2008 , 15, 665-74		54
12	Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer?. <i>Prostate</i> , 2007 , 67, 312-29	4.2	78
11	A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease. <i>Journal of the National Cancer Institute</i> , 2007 , 99, 376-85	9.7	75
10	The SERCA pump as a therapeutic target: making a "smart bomb" for prostate cancer. <i>Cancer Biology and Therapy</i> , 2005 , 4, 14-22	4.6	178
9	Development of prostate cancer treatment: the good news. <i>Prostate</i> , 2004 , 58, 211-24	4.2	67
8	Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. <i>Prostate</i> , 2003 , 54, 249-57	4.2	111
7	In vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate cancer xenografts. <i>Prostate</i> , 2000 , 45, 80-3	4.2	49

6	COMPLETE ANDROGEN BLOCKADE FOR PROSTATE CANCER: WHAT WENT WRONG?. <i>Journal of Urology</i> , 2000 , 164, 3-9	2.5	89
5	Suppression of the tumorigenicity of prostatic cancer cells by gene(s) located on human chromosome 19p13.1-13.2. <i>Prostate</i> , 1999 , 38, 46-54	4.2	31
4	Inhibition of caspase activity does not prevent the signaling phase of apoptosis in prostate cancer cells. <i>Prostate</i> , 1999 , 39, 269-79	4.2	19
3	Mechanism and role of growth arrest in programmed (apoptotic) death of prostatic cancer cells induced by thapsigargin. <i>Prostate</i> , 1997 , 33, 201-7	4.2	46
2	Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. <i>Prostate</i> , 1996 , 28, 251-65	4.2	294
1	Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer 1996 , 28, 251		9